Roche Holding AG (OTCMKTS:RHHBY) Shares Purchased by Canopy Partners LLC

Canopy Partners LLC boosted its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY) by 4.6% during the third quarter, HoldingsChannel.com reports. The firm owned 7,772 shares of the company’s stock after purchasing an additional 344 shares during the period. Canopy Partners LLC’s holdings in Roche were worth $310,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Bard Financial Services Inc. increased its stake in Roche by 112.1% during the 3rd quarter. Bard Financial Services Inc. now owns 66,500 shares of the company’s stock worth $2,657,000 after buying an additional 35,150 shares in the last quarter. GAMMA Investing LLC boosted its stake in Roche by 57.7% during the 3rd quarter. GAMMA Investing LLC now owns 7,944 shares of the company’s stock worth $317,000 after purchasing an additional 2,906 shares during the last quarter. OLD National Bancorp IN raised its position in shares of Roche by 3.2% in the second quarter. OLD National Bancorp IN now owns 265,242 shares of the company’s stock valued at $9,206,000 after buying an additional 8,146 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in Roche during the second quarter worth about $327,000. Finally, Waldron Private Wealth LLC purchased a new stake in Roche during the 2nd quarter valued at about $263,000.

Roche Stock Performance

Shares of OTCMKTS RHHBY opened at $35.44 on Friday. Roche Holding AG has a 1 year low of $29.20 and a 1 year high of $42.43. The company has a 50 day simple moving average of $38.61 and a 200-day simple moving average of $37.27.

Analyst Ratings Changes

RHHBY has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft cut Roche from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Bank of America raised Roche from a “neutral” rating to a “buy” rating in a research note on Friday, September 13th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold”.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.